Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remogliflozin and Sergliflozin in Type 2 Diabetes
NCT00291356Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2006
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of remogliflozin etabonate, Sergliflozin in type 2 diabetes mellitus (T2DM), sponsored by GSK. Started Jan 2006; status: completed.
02
Drugs
remogliflozin etabonateSergliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00291356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291356.